Premium
Erythromycin‐Associated Cholestatic Hepatitis
Author(s) -
Derby Laura E,
Jick Hershel,
Henry David A,
Dean Alan D
Publication year - 1993
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1993.tb137625.x
Subject(s) - erythromycin , cholestatic hepatitis , medicine , medical prescription , cholestatic jaundice , retrospective cohort study , confidence interval , hepatitis , hepatitis c , drug , cohort study , confounding , jaundice , pediatrics , cohort , cholestasis , gastroenterology , intensive care medicine , antibiotics , pharmacology , microbiology and biotechnology , biology
Objective To estimate the risk of cholestatic hepatitis of uncertain origin in patients who had recently received erythromycin, a drug which is known to cause this disorder. Design A retrospective cohort study using data automatically recorded on general practitioners' office computers. Setting Some 600 general practices in the United Kingdom. Subjects 366 064 people who received erythromycin. Main outcome measure Clinically documented cholestatic hepatitis of uncertain origin diagnosed 1‐45 days after a prescription for erythromycin. Results There were 13 cases of cholestatic hepatitis of uncertain origin diagnosed within 45 days of receiving erythromycin which were either characteristic of or consistent with a syndrome previously described as being associated with this drug. Conclusion The risk of cholestatic jaundice associated with erythromycin is estimated to be in the range of 3.6 per 100 000 users (95% confidence interval, 1.9–6.1).